Skip to main content
Erschienen in: European Radiology 10/2021

31.03.2021 | Hepatobiliary-Pancreas

Added value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort

verfasst von: Jeongin Yoo, Se Hyung Kim, Sun Kyung Jeon, Jae Seok Bae, Joon Koo Han

Erschienen in: European Radiology | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To investigate an additional value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing suspected pancreatic neuroendocrine neoplasms (NENs) in a large study cohort.

Methods

This retrospective study included 167 patients who underwent [68Ga]Ga-DOTA-TOC PET/CT for suspected pancreatic NENs detected by contrast-enhanced CT (n = 153) and/or MRI (n = 85). Two board-certified radiologists independently reviewed CT and/or MRI as well as [68Ga]Ga-DOTA-TOC PET/CT and scored the probability of NEN on a 5-point scale. Radiologists’ diagnostic performances with and without [68Ga]Ga-DOTA-TOC PET/CT were compared using pathologic findings as the standard of reference.

Results

All 167 patients were pathologically diagnosed with NENs (n = 131) or non-NENs (n = 36) by surgery (n = 93) or biopsy (n = 74). The non-NEN group included focal pancreatitis (n = 7), gastrointestinal stromal tumor (n = 6), serous cystadenoma (n = 5), metastatic renal cell carcinoma (n = 4), intrapancreatic accessory spleen (n = 4), ductal adenocarcinoma (n = 3), solid pseudopapillary neoplasm (n = 2), intraductal papillary mucinous carcinoma (n = 1), adenosquamous carcinoma (n = 1), schwannoma (n = 1), paraganglioma (n = 1), and solitary fibrous tumor (n = 1). Radiologists’ diagnostic performance significantly improved after the addition of [68Ga]Ga-DOTA-TOC PET/CT (AUC of CT: 0.737 vs. 0.886 for reviewer 1 [p = 0.0004]; 0.709 vs. 0.859 for reviewer 2 [p = 0.0002], AUC of MRI: 0.748 vs. 0.872 for reviewer 1 [p = 0.023]; 0.670 vs. 0.854 for reviewer 2 [p = 0.001]). [68Ga]Ga-DOTA-TOC PET/CT significantly improved sensitivity (CT: 87.4% vs. 96.6% for reviewer 1 [p = 0.001]; 74.8% vs. 92.5% for reviewer 2 [p = 0.0001], MRI: 86.9% vs. 98.4% for reviewer 1 [p = 0.016]; 70.5% vs. 91.8% for reviewer 2 [p = 0.002]).

Conclusions

[68Ga]Ga-DOTA-TOC PET/CT provided an additional value over conventional CT or MRI for the characterization of suspected pancreatic NENs.

Key Points

• [ 68 Ga]Ga-DOTA-TOC PET/CT could provide additional value over conventional CT and/or MRI for the exact characterization of suspected pancreatic NENs by increasing AUC values and sensitivity.
• Diagnostic improvement was significant, especially in NENs showing an atypical enhancement pattern.
• The inter-observer agreement was improved when [ 68 Ga]Ga-DOTA-TOC PET/CT was added to CT and/or MRI.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Halfdanarson TR, Rabe K, Rubin J, Petersen GM (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733CrossRef Halfdanarson TR, Rabe K, Rubin J, Petersen GM (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733CrossRef
2.
Zurück zum Zitat Choe J, Kim KW, Kim HJ et al (2019) What is new in the 2017 World Health Organization classification and 8th American Joint Committee on Cancer staging system for pancreatic neuroendocrine neoplasms? Korean J Radiol 20:5–17CrossRef Choe J, Kim KW, Kim HJ et al (2019) What is new in the 2017 World Health Organization classification and 8th American Joint Committee on Cancer staging system for pancreatic neuroendocrine neoplasms? Korean J Radiol 20:5–17CrossRef
3.
Zurück zum Zitat Lloyd R, Osamura R, Klöppel G, Rosai J (2017) WHO Classification of Tumours of Endocrine Organs, 4th edn, vol 10. IARC Press, Lyon Lloyd R, Osamura R, Klöppel G, Rosai J (2017) WHO Classification of Tumours of Endocrine Organs, 4th edn, vol 10. IARC Press, Lyon
4.
Zurück zum Zitat Kim SS (2018) Pancreas neuroendocrine tumor and its mimics: review of cross-sectional imaging findings for differential diagnosis. Soonchunhyang Med Sci 24:117–121CrossRef Kim SS (2018) Pancreas neuroendocrine tumor and its mimics: review of cross-sectional imaging findings for differential diagnosis. Soonchunhyang Med Sci 24:117–121CrossRef
5.
Zurück zum Zitat NCCN clinical practice guidelines in oncology. Neuroendocrine tumors. Version 3. National Comprehensive Cancer Network Web site NCCN clinical practice guidelines in oncology. Neuroendocrine tumors. Version 3. National Comprehensive Cancer Network Web site
6.
Zurück zum Zitat Hope TA, Bergsland EK, Bozkurt MF et al (2018) Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med 59:66–74CrossRef Hope TA, Bergsland EK, Bozkurt MF et al (2018) Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med 59:66–74CrossRef
7.
Zurück zum Zitat Kayani I, Bomanji JB, Groves A et al (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455CrossRef Kayani I, Bomanji JB, Groves A et al (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455CrossRef
8.
Zurück zum Zitat Kim DW, Kim HJ, Kim KW et al (2015) Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol 25:1375–1383CrossRef Kim DW, Kim HJ, Kim KW et al (2015) Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol 25:1375–1383CrossRef
9.
Zurück zum Zitat Ciaravino V, De Robertis R, Tinazzi Martini P et al (2018) Imaging presentation of pancreatic neuroendocrine neoplasms. Insights Imaging 9:943–953CrossRef Ciaravino V, De Robertis R, Tinazzi Martini P et al (2018) Imaging presentation of pancreatic neuroendocrine neoplasms. Insights Imaging 9:943–953CrossRef
10.
Zurück zum Zitat Rha SE, Jung SE, Lee KH, Ku YM, Byun JY, Lee JM (2007) CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur J Radiol 62:371–377CrossRef Rha SE, Jung SE, Lee KH, Ku YM, Byun JY, Lee JM (2007) CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur J Radiol 62:371–377CrossRef
11.
Zurück zum Zitat Lee H, Ahn JM, Kang Y et al (2018) Evaluation of the subscapularis tendon tears on 3T magnetic resonance arthrography: comparison of diagnostic performance of T1-weighted spectral presaturation with inversion-recovery and T2-weighted turbo spin-echo sequences. Korean J Radiol 19:320–327CrossRef Lee H, Ahn JM, Kang Y et al (2018) Evaluation of the subscapularis tendon tears on 3T magnetic resonance arthrography: comparison of diagnostic performance of T1-weighted spectral presaturation with inversion-recovery and T2-weighted turbo spin-echo sequences. Korean J Radiol 19:320–327CrossRef
12.
Zurück zum Zitat Kantorovich V, Pacak K (2010) Pheochromocytoma and paraganglioma. Prog Brain Res 182:343–373CrossRef Kantorovich V, Pacak K (2010) Pheochromocytoma and paraganglioma. Prog Brain Res 182:343–373CrossRef
13.
Zurück zum Zitat Sadowski SM, Neychev V, Millo C et al (2016) Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol 34:588–596CrossRef Sadowski SM, Neychev V, Millo C et al (2016) Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol 34:588–596CrossRef
14.
Zurück zum Zitat Kumar R, Sharma P, Garg P et al (2011) Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 21:2408–2416CrossRef Kumar R, Sharma P, Garg P et al (2011) Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 21:2408–2416CrossRef
15.
Zurück zum Zitat Gallotti A, Johnston RP, Bonaffini PA et al (2013) Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy. AJR Am J Roentgenol 200:355–362CrossRef Gallotti A, Johnston RP, Bonaffini PA et al (2013) Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy. AJR Am J Roentgenol 200:355–362CrossRef
16.
Zurück zum Zitat Hofman MS, Lau WE, Hicks RJ (2015) Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500–516CrossRef Hofman MS, Lau WE, Hicks RJ (2015) Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500–516CrossRef
17.
Zurück zum Zitat Nadebaum DP, Lee ST, Nikfarjam M, Scott AM (2018) Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature. World J Nucl Med 17:195–197CrossRef Nadebaum DP, Lee ST, Nikfarjam M, Scott AM (2018) Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature. World J Nucl Med 17:195–197CrossRef
18.
Zurück zum Zitat Reubi JC, Kvols L (1992) Somatostatin receptors in human renal cell carcinomas. Cancer Res 52:6074–6078PubMed Reubi JC, Kvols L (1992) Somatostatin receptors in human renal cell carcinomas. Cancer Res 52:6074–6078PubMed
19.
Zurück zum Zitat Deroose CM, Hindié E, Kebebew E et al (2016) Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med 57:1949–1956CrossRef Deroose CM, Hindié E, Kebebew E et al (2016) Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med 57:1949–1956CrossRef
20.
Zurück zum Zitat Rust E, Hubele F, Marzano E et al (2012) Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging 12:173CrossRef Rust E, Hubele F, Marzano E et al (2012) Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging 12:173CrossRef
21.
Zurück zum Zitat Virgolini I, Gabriel M, Kroiss A et al (2016) Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUV max reference range for management of pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 43:2072–2083CrossRef Virgolini I, Gabriel M, Kroiss A et al (2016) Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUV max reference range for management of pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 43:2072–2083CrossRef
Metadaten
Titel
Added value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort
verfasst von
Jeongin Yoo
Se Hyung Kim
Sun Kyung Jeon
Jae Seok Bae
Joon Koo Han
Publikationsdatum
31.03.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 10/2021
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-021-07859-0

Weitere Artikel der Ausgabe 10/2021

European Radiology 10/2021 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.